Ann: Quarterly Activities Report, page-4

Great to have an update , plenty of detail in there

The DEP demonstrated that the highest dose tested, 200 mg BID, was safe and achieved robust systemic reduction of lysyl oxidase activity; this dose was therefore selected for the CEP. Twentyfour patients (median age 72 years) with relapsed or refractory MF were recruited into the CEP and 54% (13/24) completed 24 weeks of treatment. PXS-5505 was well tolerated and reached steady state concentrations by Day 28. Over the 24-week treatment period preliminary indications of clinical efficacy, including a reduction in BM collagen, were evident. Overall, these data support continued investigation of PXS-5505.

SNT 6302 to be superseded by the newly formulated SNT 9465 which requires far less Clinical Consultations and allows the Trial Participant to apply the Formula in house,,, thats a huge difference for the end user and reduces overall cost to the patient once approved..

Nicely formatted Share Holder Update ,,, but what about "Market Updates and market Interactions"? those that have already invested are on board SNT IMHO needs to be pushing this detail to market..

Looking forward to the next Phase II Interim Data Announcement but backed with some external Promotion to market,,,, SNT "You can't Sell a Secret" NZT